• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Moleculin Biotech Inc.

    9/10/25 4:17:44 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBRX alert in real time by email
    S-8 1 mbrx20250908_s8.htm FORM S-8 mbrx20250908_s8.htm

    As filed with the Securities and Exchange Commission on September 10, 2025

    Registration No. 333-

     

       

       

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    Moleculin Biotech, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    47-4671997

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer Identification Number)

     

    5300 Memorial Drive, Suite 950

       

    Houston, Texas

     

    77007

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Moleculin Biotech, Inc. 2024 Stock Plan

    (Full title of the plans)

     

    Walter V. Klemp, Chief Executive Officer

    5300 Memorial Drive, Suite 950

    Houston, Texas 77007

    (Name and address of agent for service)

     

    Copies to:

     

    Cavas S. Pavri, Esq.

    ArentFox Schiff LLP

    1717 K Street, NW

    Washington, DC 20006

    (202) 724-6847

    Facsimile: (202) 778-6460

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1.  Plan Information.

     

    The Registrant shall deliver or cause to be delivered documents containing the information specified by Part I of this Registration Statement to participants in the Moleculin Biotech, Inc. 2024 Stock Plan (the “2024 Plan”) to which this Registration Statement relates, as specified in Rule 428(b)(1) promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”). The Registrant is not filing such documents with the Commission, but these documents (along with the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II hereof) constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    Item 2.  Registrant Information and Employee Plan Annual Information.

     

    The written statement required by Item 2 is included in documents sent or given to participants in the 2024 Plans covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

     

    The Commission allows us to “incorporate by reference” certain information we have filed with the Commission into this Registration Statement, which means that we are disclosing important information to you by referring you to other information we have filed with the Commission. The information we incorporate by reference is considered part of this Registration Statement. We specifically are incorporating by reference the following documents filed with the Commission (excluding those portions of any Current Report on Form 8-K that are furnished and not deemed “filed” pursuant to the General Instructions of Form 8-K): 

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 (filed on March 21, 2025), as amended on Form 10-K/A (filed on April 18, 2025), as amended on Form 10-K/A (filed on April 30, 2025);

     

     

    (b)

    The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 (filed on May 13, 2025), and for the quarter ended June 30, 2025 (filed on August 12, 2025);

     

     

    (c)

    The Registrant’s Current Reports on Form 8-K filed on February 10, 2025; February 13, 2025; February 26, 2025; April 9, 2025; April 25, 2025; May 9, 2025; May 23, 2025; June 4, 2025; June 18, 2025; June 23, 2025; June 27, 2025; July 11, 2025; August 18, 2025; August 27, 2025; and August 29, 2025;

     

     

    (d)

    The Registrant’s Definitive Proxy Statement on Schedule 14A filed on July 8, 2025; and

     

     

    (e)

    The description of our common stock, par value $0.001 per share contained in Exhibit 4.10 to our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 24, 2022, including any amendments thereto or reports filed for the purposes of updating this description.

     

    Additionally, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of a Current Report on Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference and to be a part of this Registration Statement from the date of filing of such documents. 

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4.

    Description of Securities.

     

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.

    Indemnification of Directors and Officers.

     

    The Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and Amended and Restated Bylaws (the “Bylaws”) of Moleculin Biotech, Inc. ("MBI") authorize it to indemnify directors, officers, employees and agents of MBI against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement, actually and reasonably incurred in connection with any action, suit or proceeding, if the party to be indemnified acted in good faith and in a manner that he or she reasonably believed to be in or not opposed to the best interests of MBI, and, with respect to any criminal action or proceeding, such party had no reasonable cause to believe his conduct was unlawful. The Certificate of Incorporation and the Bylaws of MBI also authorize it to indemnify directors, officers, employees and agents of MBI who are or were a party to or threatened to be a party to, any threatened, pending, or completed action or suit by or in the right of MBI to procure a judgment in its favor by reason of the fact the he or she was a director, officer, employee or agent of MBI or of another entity at the request of MBI, against expenses (including reasonable attorneys’ fees) actually and reasonably incurred by him or her in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of MBI.

     

    MBI has entered into indemnity agreements with its directors and officers and may in the future enter into such agreements with other employees or agents. These agreements, together with the Bylaws and Certificate of Incorporation, may require MBI, among other things, to indemnify employees or agents against certain liabilities that may arise by reason of their status or service as directors (other than liabilities resulting from willful misconduct of a culpable nature), to advance expenses to them as they are incurred, provided that they undertake to repay the amount advanced if it is ultimately determined by a court that they are not entitled to indemnification, and to obtain and maintain directors’ and officers’ insurance if available on reasonable terms.

     

    MBI’s Certificate of Incorporation provides that directors shall have no personal liability to MBI or its stockholders for monetary damages for breach of fiduciary duty as a director, except (i) for any breach of a director’s duty of loyalty to MBI or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under section 174 of the General Corporation Law of Delaware as it may from time to time be amended or any successor provision thereto, or (iv) for any transaction from which a director derived an improper personal benefit.

     

    MBI currently has directors’ and officers’ liability insurance. Delaware General Corporation Law, Section 145, and the Certificate of Incorporation and Bylaws of MBI provide for the indemnification of officers, directors and other corporate agents in terms sufficiently broad to indemnify such persons, under certain circumstances, for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, MBI has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

     

    Item 7.

    Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

    Item 8.

    Exhibits.

     

    The following exhibits are filed as a part of or incorporated by reference into this Registration Statement:

     

    Exhibit No.

    Description of Exhibit

       

    4.1

    Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to exhibit 3.1 of the Form S-1/A filed March 21, 2016)

       

    4.2

    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed May 24, 2019)

       

    4.3

    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed January 29, 2021)

       

    4.4

    Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed March 19, 2024)

       

    4.5

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc., dated August 21, 2025 (incorporated by reference to Exhibit 3.1 of the Form 8-K filed August 27, 2025)

       

    4.6

    Fourth Amended and Restated Bylaws of Moleculin Biotech., Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed December 21, 2023)

       

    5#

    Opinion of ArentFox Schiff LLP

       

    23.1#

    Consent of Grant Thornton LLP

       

    23.2#

    Consent of ArentFox Schiff LLP (included in Exhibit 5)

       

    24

    Power of Attorney (included in the signature pages of this Registration Statement)

       

    99.1#

    Moleculin Biotech, Inc. 2024 Stock Plan

       

    99.2#

    Forms of award agreements under Moleculin Biotech, Inc. 2024 Stock Plan.

       

    107#

    Filing Fee Table

     

     

    #

    Filed herewith.

     

     

     

     

    Item 9.

    Undertakings.

     

    (a)        The Registrant hereby undertakes:

     

    (1)        To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act.

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (2)        That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)        To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)        The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)        Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Houston, Texas, on September 10, 2025.

     

     

    MOLECULIN BIOTECH, INC.

     
           
     

    By:

    /s/ Walter V. Klemp

     
       

    Walter V. Klemp

     
       

    Chief Executive Officer

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Walter V. Klemp and Jonathan P. Foster, or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and ratifying and confirming all that such attorney-in-fact and agent or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:

     

     

    SIGNATURE

     

    TITLE

     

    DATE

             

    /s/ Walter V. Klemp

           

    Walter V. Klemp

     

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

     

    September 10, 2025

             

    /s/ Jonathan P. Foster

           

    Jonathan P. Foster

     

    Chief Financial Officer and Executive Vice President

     

    September 10, 2025

       

    (Principal Financial Officer and Principal Accounting Officer)

       

    /s/ Robert George

           

    Robert George

     

    Director

     

    September 10, 2025

             

    /s/ Michael Cannon

           

    Michael Cannon

     

    Director

     

    September 10, 2025

             

    /s/ John Climaco

           

    John Climaco

     

    Director

     

    September 10, 2025

             

    /s/ Elizabeth Cermak

           

    Elizabeth Cermak

     

    Director

     

    September 10, 2025

             

    /s/ Joy Yan

           

    Joy Yan

     

    Director

      September 10, 2025

     

     
    Get the next $MBRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBRX

    DatePrice TargetRatingAnalyst
    6/9/2025$4.00Buy
    H.C. Wainwright
    2/12/2025Buy → Hold
    Maxim Group
    7/18/2022$14.00Outperform
    Oppenheimer
    More analyst ratings

    $MBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Klemp Walter V bought $250,000 worth of shares (675,675 units at $0.37), converted options into 12,740 shares and covered exercise/tax liability with 3,104 shares, increasing direct ownership by 1,176% to 743,607 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:11 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science Officer Picker Donald H converted options into 2,844 shares and covered exercise/tax liability with 693 shares, increasing direct ownership by 27% to 10,152 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:34:52 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial

    European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjects by end of September On track to recruit to 45 patients in Q4 25 for initial data unblinding HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced updates to its active site status and recruitment for its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlle

    9/9/25 8:45:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

    Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that it has enrolled the first two subjects, and treated one, in the European Union (EU) in its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as "Ara-C" and for which the combination of An

    9/8/25 8:30:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

    HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 16,216,216 shares of common stock of the Company originally issued in June 2025 at an exercise price of $0.37 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to an effective registration statement on Form S-1 (F

    8/28/25 8:30:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

    H.C. Wainwright resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $4.00

    6/9/25 7:52:11 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Biotech downgraded by Maxim Group

    Maxim Group downgraded Moleculin Biotech from Buy to Hold

    2/12/25 8:44:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Moleculin Biotech with a new price target

    Oppenheimer resumed coverage of Moleculin Biotech with a rating of Outperform and set a new price target of $14.00

    7/18/22 9:16:10 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    SEC Filings

    View All

    SEC Form S-8 filed by Moleculin Biotech Inc.

    S-8 - Moleculin Biotech, Inc. (0001659617) (Filer)

    9/10/25 4:17:44 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

    9/9/25 8:45:10 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

    9/8/25 4:42:07 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Klemp Walter V bought $250,000 worth of shares (675,675 units at $0.37), converted options into 12,740 shares and covered exercise/tax liability with 3,104 shares, increasing direct ownership by 1,176% to 743,607 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:11 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    12/27/23 7:32:37 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    Leadership Updates

    Live Leadership Updates

    View All

    Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

    40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of global healthcare markets. He has held senior executive roles across diverse regions, including overseeing U.S. supply c

    7/17/25 8:25:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

    Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON, Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the appointment of Daniel D. Von Hoff, M.D., F.A.C.P., FASCO, FAACR to its Annamycin Scientific Advisory Board. Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "We are very pleased to welco

    11/4/24 8:30:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

    Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Company's AML clinical development program as well as data demonstrated to dateOngoing development progress of Annamycin toward pivotal AML study in 2024 with potential qualification for an accelerated approval pathwayHOUSTON, May 2, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will host a virtual AML Clinica

    5/2/24 9:00:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML  Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company's ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM ET HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug

    5/14/25 7:30:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

    HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

    5/7/25 9:00:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

    – Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site activated – Initial data readout of the Phase 3 MIRACLE trial expected in the second half of 2025 – Company to host conference call and webcast today, Monday, March 24th at 8:30 AM ET HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported its financial results

    3/24/25 7:05:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Moleculin Biotech Inc.

    SC 13G - Moleculin Biotech, Inc. (0001659617) (Subject)

    2/14/24 3:43:13 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    2/10/21 11:28:21 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care